Soros Fund Management’s SpringWorks Therapeutics SWTX Stock Holding History

Soros Fund Management’s Portfolio SWTX Stock Details SWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-501,989	Closed	-$23.6M	–	239
2025 Q2	$23.6M	Buy	501,989 +45,157	+10%	+$2.01M	0.3%	89
2025 Q1	$20.2M	Sell	456,832 -143,638	-24%	-$6.61M	0.3%	87
2024 Q4	$21.7M	Buy	600,470 +41,149	+7%	+$1.44M	0.33%	82
2024 Q3	$17.9M	Buy	559,321 +174,321	+45%	+$6.51M	0.26%	88
2024 Q2	$14.5M	Buy	385,000 +181,054	+89%	+$7.62M	0.26%	96
2024 Q1	$10M	Buy	+203,946	New	+$9.43M	0.17%	122

Other funds holding SWTX

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Soros Fund Management's SWTX Position: Q3 2025 in Review

Soros Fund Management sold out of SpringWorks Therapeutics (SWTX) in Q3 2025, closing a stake of 501,989 shares — an estimated $23.6M sold.

Soros Fund Management first reported a position in SWTX in Q1 2024 and held it in 6 quarters. The position peaked at $23.6M in Q2 2025. 3 funds tracked by Wall St. Rank hold SWTX as of Q3 2025.

Soros Fund Management reported no remaining SpringWorks Therapeutics position as of Q3 2025 after selling out during the quarter.
Soros Fund Management sold 501,989 SpringWorks Therapeutics shares in Q3 2025, an estimated $23.6M.
Soros Fund Management first reported a position in SpringWorks Therapeutics in Q1 2024 and held it in 6 quarters.
Soros Fund Management's SpringWorks Therapeutics position peaked at $23.6M in Q2 2025.
3 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q3 2025.

Based on Soros Fund Management's 13F filing for Q3 2025, filed 14 Nov 2025.